Background non-rheumatic calcific aortic valve disease (nrCAVD) is a valvular disease characterized by progressive calcification of the aortic valve that can lead to progressive left heart failure and death. This study reports on the global burden of CAVD, utilizing all available data and using the Global Burden of Disease (GBD) study methodology to understand the epidemiology of this widely prevalent disease. Methods Prior to the current effort, the burden of CAVD was included in GBD as a non-specific contributor to “valvular heart disease” burden. In this study, CAVD was distinguished as its own cause of death and disability in GBD, producing comparable and consistent estimates of CAVD burden. We used epidemiological and vital registry data to estimate the non-fatal and fatal burden of CAVD in 204 countries and 21 territories from 1990 to 2021 using standard GBD modelling approaches. Results In 2021, there were an estimated 13,320,896.13 (95% uncertainty interval [UI] 11,422,539.18 to 15,249,410.95) prevalent cases of CAVD globally. Of these, 6,018,666.77 (5,139,855.53 to 6,897,468.51) were in females (45%) and 7,302,229.37 (6,260,246.93 to 8,340,870.42) in males (55%). The age-standardised prevalence was 158.35 cases per 100 000 population (95% UI 135.92 – 181.00). Prevalence increased with age such that the highest prevalence was among individuals aged 90–94 years. In 2021, there were 142,205.00? (120,674.91 – 155,574.74) attributed to PAH globally, with an age-standardised mortality rate of 1.83 deaths from CAVD per 100 000 population (1.54 – 2.00). The burden of disease appears to be improving over time.

The authors have declared no competing interest.

The author(s) received no specific funding for this work.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Not Applicable